GT Biopharma, Inc.
GTBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000109657
No open-market purchases or sales by GT Biopharma, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $1.02M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in GT Biopharma, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- 0 vs. Q2 2025
- Shares held
- 374.2K
- +175.5K (+88.4%) vs. Q2 2025
- Total value
- $222.2K
- −$489.1K (−68.8%) vs. Q2 2025
- New holders
- 3
- 4 more added
- Sold out
- 3
- 4 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GTBP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 59 | $1.02M |
| Q1 2026 | 42 | $656.7K |
| Q4 2025 | 38 | $373.7K |
| Q3 2025 | 21 | $222.2K |
| Q2 2025 | 21 | $711.3K |
| Q1 2025 | 20 | $220.5K |
| Q4 2024 | 19 | $279.1K |
| Q3 2024 | 16 | $203.8K |
| Q2 2024 | 17 | $296.8K |
| Q1 2024 | 17 | $348.6K |
| Q4 2023 | 34 | $893.1K |
| Q3 2023 | 33 | $849.9K |
| Q2 2023 | 37 | $1.11M |
| Q1 2023 | 36 | $3.05M |
| Q4 2022 | 36 | $5.62M |
| Q3 2022 | 35 | $4.36M |
| Q2 2022 | 48 | $9.28M |
| Q1 2022 | 58 | $12.9M |
| Q4 2021 | 55 | $16.7M |
| Q3 2021 | 54 | $32.1M |
| Q2 2021 | 50 | $69.9M |
| Q1 2021 | 21 | $3.98M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding GT Biopharma, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 1 | $1 | 0.00% | 00.0% | Unchanged |
| Allworth Financial LP | 1 | $1 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 5 | $3 | 0.00% | −1−16.7% | Reduced |
| Blue Bell Private Wealth Management, LLC | 10 | $6 | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 16 | $9 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 24 | $14 | 0.00% | −5−17.2% | Reduced |
| Jones Financial Companies LLLP | 300 | $230 | 0.00% | 00.0% | Unchanged |
| Clearstead Advisors, LLC | 865 | $508 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,704 | $999 | 0.00% | +1,254+278.7% | Added |
| UBS Group AG | 2,626 | $1.54K | 0.00% | −3,184−54.8% | Reduced |
| Newbridge Financial Services Group, Inc. | 3,750 | $2.20K | 0.00% | +1,000+36.4% | Added |
| Advisor Group Holdings, Inc. | 5,073 | $4.70K | 0.00% | −6,383−55.7% | Reduced |
| BlackRock, Inc. | 9,737 | $5.71K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 10,012 | $5.87K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 10,504 | $6.25K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 14,015 | $8.22K | 0.00% | +10,000+249.1% | Added |
| Two Sigma Securities, LLC | 17,065 | $10.0K | 0.00% | +17,065 | New |
| Geode Capital Management, LLC | 23,966 | $14.3K | 0.00% | +129+0.5% | Added |
| Citadel Advisors LLC | 39,633 | $23.6K | 0.00% | +39,633 | New |
| Bank of Montreal | 92,530 | $54.6K | 0.00% | 00.0% | Unchanged |
| DRW Securities, LLC | 142,380 | $83.5K | 0.00% | +142,380 | New |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −26,300−100.0% | Sold out |
| Mount Yale Investment Advisors, LLC | 0 | $0 | 0.00% | −46−100.0% | Sold out |
| Front Row Advisors LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |